Monoclonal Antibodies and Antivirals against SARS-CoV-2 Reduce the Risk of Long COVID: A Retrospective Propensity Score-Matched Case–Control Study

Long COVID is a complex condition affecting quality of life, with limited therapeutic options. We investigated the occurrence of long COVID in subjects receiving early therapy with monoclonal antibodies (mAbs) or antivirals to reduce the risk of COVID-19 progression. In this retrospective study we e...

Descripción completa

Detalles Bibliográficos
Autores principales: Cimellaro, Antonio, Addesi, Desirée, Cavallo, Michela, Spagnolo, Francesco, Suraci, Edoardo, Cordaro, Raffaella, Spinelli, Ines, Passafaro, Francesco, Colosimo, Manuela, Pintaudi, Medea, Pintaudi, Carmelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775930/
https://www.ncbi.nlm.nih.gov/pubmed/36551891
http://dx.doi.org/10.3390/biomedicines10123135

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775930/
https://www.ncbi.nlm.nih.gov/pubmed/36551891
http://dx.doi.org/10.3390/biomedicines10123135

Ejemplares similares